CNMD · Insider Trading
CONMED Corporation
Every open-market purchase and sale reported by CNMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Kim Kelderman | Director | M | +500 | — |
| 2026-07-17 | John E Gallagher | Executive Vice President & CFO | A | +92,465 deriv. | — |
| 2026-07-02 | Celine Christine Martin | Director | A | +5,603 deriv. | — |
| 2026-07-02 | Jeffrey B. Mirviss | Director | A | +5,603 deriv. | — |
| 2026-06-03 | David M. Bronson | Director | M | +668 | — |
| 2026-06-03 | LaVerne H Council | Director | M | +668 | — |
| 2026-06-03 | Charles Farkas | Director | M | +668 | — |
| 2026-06-03 | Mark Kaye | Director | M | +668 | — |
| 2026-06-03 | Kim Kelderman | Director | A | +5,772 deriv. | — |
| 2026-06-03 | Barbara J Schwarzentraub | Director | M | +668 | — |
| 2026-04-02 | Pat Beyer | President & CEO | A | +28,145 deriv. | — |
| 2026-03-18 | Peter K Shagory | EVP, STRAT & CORP DEVT | A | +16,926 deriv. | — |
| 2026-03-18 | Hollie K Foust | General Counsel & Corp Sec | A | +18,563 deriv. | — |
| 2026-03-18 | Matthew Schabacker | VP GM Advanced Surgical | A | +17,471 deriv. | — |
| 2026-03-18 | Brent Lalomia | Executive VP RA, QA | A | +17,198 deriv. | — |
| 2026-03-18 | John D. Ferrell | Executive Vice President - HR | A | +16,926 deriv. | — |
| 2026-03-10 | Brent Lalomia | Executive VP RA, QA | MIXED | +49 | −$1.04K |
| 2026-03-04 | Pat Beyer | President & CEO | A | +97,058 deriv. | — |
| 2026-03-04 | Peter K Shagory | EVP, STRAT & CORP DEVT | A | +20,281 deriv. | — |
| 2026-03-04 | John D. Ferrell | Executive Vice President - HR | A | +20,281 deriv. | — |
| 2026-03-04 | Matthew Schabacker | VP GM Advanced Surgical | A | +21,473 deriv. | — |
| 2026-03-04 | Johonna Marie Pelletier | Treasurer and VP, Tax | A | +5,896 deriv. | — |
| 2026-03-04 | Andrew James Moller | VP Corporate Controller | A | +5,896 deriv. | — |
| 2026-03-04 | Brent Lalomia | Executive VP RA, QA | A | +20,876 deriv. | — |
| 2026-03-04 | Hollie K Foust | General Counsel & Corp Sec | A | +23,859 deriv. | — |
| 2026-02-26 | Mark Kaye | Director | M | +152 | — |
| 2025-11-24 | Richard Glaze | Chief Information Officer | Sell | −257 | −$10.59K |
| 2025-11-21 | Richard Glaze | Chief Information Officer | MIXED | +257 | −$4.79K |
| 2025-11-07 | Todd W Garner | Executive Vice President & CFO | Sell | −3,500 | −$150.50K |
| 2025-11-05 | Hollie K Foust | General Counsel & Corp Sec | MIXED | +2,886 | −$50.92K |
| 2025-11-03 | Todd W Garner | Executive Vice President & CFO | MIXED | +5,336 | −$95.22K |
| 2025-09-15 | Charles Farkas | Director | Sell | −2,000 | −$107.05K |
| 2025-09-09 | Kim Kelderman | Director | A | +6,727 deriv. | — |
| 2025-08-08 | Todd W Garner | Executive Vice President & CFO | Sell | −598 | −$31.37K |
| 2025-06-04 | David M. Bronson | Director | M | +479 | — |
| 2025-06-04 | LaVerne H Council | Director | M | +479 | — |
| 2025-06-04 | Charles Farkas | Director | M | +479 | — |
| 2025-06-04 | Mark Kaye | Director | A | +8,729 deriv. | — |
| 2025-06-04 | Brian Concannon | Director | M | +479 | — |
| 2025-06-04 | Barbara J Schwarzentraub | Director | M | +479 | — |
| 2025-06-04 | Martha Goldberg Aronson | Director | M | +479 | — |
| 2025-05-30 | Charles Farkas | Director | MIXED | +34 | −$29 |
| 2025-05-21 | John L Workman | Director | M | +479 | +$28.66K |
| 2025-05-15 | Stephan Epinette | VP GM International | A | +17,144 deriv. | — |
| 2025-05-06 | Charles Farkas | Director | Sell | −4,000 | −$227.77K |
| 2025-05-01 | Matthew Schabacker | VP GM Advanced Surgical | A | +31,675 deriv. | — |
| 2025-04-08 | Todd W Garner | Executive Vice President & CFO | A | +371 | +$21.28K |
| 2025-03-17 | Peter K Shagory | EVP, STRAT & CORP DEVT | MIXED | +184 | −$4.52K |
| 2025-03-11 | Brent Lalomia | Vice President QA and RA | MIXED | +49 | −$1.63K |
| 2025-03-05 | Todd W Garner | Executive Vice President & CFO | A | +61,475 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Curt R Hartman | President and CEO | 93,496 | $4.31M |
| John L Workman | Director | 20,891 | $962.03K |
| David M. Bronson | Director | 17,909 | $824.71K |
| Charles Farkas | Director | 15,527 | $715.02K |
| Johonna Marie Pelletier | Treasurer and VP, Tax | 15,434 | $710.74K |
| Martha Goldberg Aronson | Director | 14,391 | $662.71K |
| Pat Beyer | President & CEO | 10,807 | $497.66K |
| Brian Concannon | Director | 10,116 | $465.84K |
| Barbara J Schwarzentraub | Director | 6,454 | $297.21K |
| LaVerne H Council | Director | 4,716 | $217.17K |
| Peter K Shagory | EVP, STRAT & CORP DEVT | 3,896 | $179.44K |
| Hollie K Foust | General Counsel & Corp Sec | 2,886 | $132.90K |
| John D. Ferrell | Executive Vice President - HR | 2,402 | $110.61K |
| Todd W Garner | Executive Vice President & CFO | 1,836 | $84.55K |
| Brent Lalomia | Executive VP RA, QA | 941 | $43.34K |
| Mark Kaye | Director | 820 | $37.76K |
| Kim Kelderman | Director | 500 | $23.02K |
| Edward A. Clifford | VP Global Manufacturing | 378 | $17.41K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CNMD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.